-transparent.png){kind=logo}
We performed a Phase I/II study of the administration of recombinant human GM-CSF to patients suffering from severe bone marrow failure, either due to aplastic anemia or myelodysplastic syndrome. Doses ranging from 15 micrograms/m2 to 480 micrograms/m2 were administered as an intravenous infusion daily for 7 days. Temporary improvements were seen in granulocyte counts, monocyte counts and reticulocyte counts. There was no reduction in erythrocyte transfusion requirements and no effect was observed on platelet counts. There was only minimal toxicity consisting of transient low back discomfort, anorexia, myalgias/arthralgias, and low grade fever. Our data suggest that prolonged use of GM-CSF might benefit some patients with severe marrow failure.
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
August 1988,
Behring Institute Mitteilungen,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
September 1991,
Bone marrow transplantation,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
August 1988,
Behring Institute Mitteilungen,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
January 1992,
Infection,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
March 1995,
Nihon rinsho. Japanese journal of clinical medicine,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
November 1999,
Nihon rinsho. Japanese journal of clinical medicine,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
May 1991,
Blood,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
September 1996,
Zhonghua yi xue za zhi,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
August 1994,
The Journal of dermatology,
J H Antin, and
B R Smith, and
W Holmes, and
R N David, and
S Rosenthal
January 1990,
Progress in clinical and biological research,
